In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Eidos Therapeutics Inc.

Division of BridgeBio Pharma Inc.
http://eidostx.com

Latest From Eidos Therapeutics Inc.

Finance Watch: Two New IPOs – IGM In the US, Henlius In Hong Kong – Gross Nearly $600m

Public Company Edition: IGM raised $175m to advance its IgM antibodies and Henlius brought in $410m for its novel drug and biosimilar platforms. Also, Acadia follow-on brings in $250m, PTC sells $350m worth of stock and debt, and Karyopharm royalty deal totals $150m.

Financing Business Strategies

Deal Watch: Castle Creek Likes Partner Fibrocell Enough To Buy It

Dermatology-focused regenerative medicine firm Fibrocell has been reviewing strategic opportunities for more than a year; April’s FCX-007 license deal with Castle Creek results in buyout.

Deals Business Strategies

After IPO, BridgeBio Looks To Tuck Eidos Back Into Its Flock

Is Eidos a goose that could lay a golden egg? BridgeBio wants to own it all, instead of two-thirds, in case its subsidiary's lead program in TTR amyloidosis succeeds in Phase III.

Deals M & A

Pharma Intelligence Congratulates The CARE Awards Winners

The fourth annual CARE Awards returned to Boston, Massachusetts, 2 May to once again recognize and commend key achievements across the spectrum of drug development that took place in 2018.
Clinical Trials Innovation
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Metabolic Disorders
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • BridgeBio Pharma Inc.
  • Senior Management
  • Neil Kumar, PhD, CEO
    Christine Siu, CFO
    Jonathan Fox, MD, PhD, Pres. & CMO
    Uma Sinha, PhD, CSO
  • Contact Info
  • Eidos Therapeutics Inc.
    Phone: (415) 887-1471
    101 Montgomery St
    Suite 2550
    San Francisco, CA 94101
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register